NCT07923383
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
AUC for CYP isoform specific substrates midazolam, omeprazole, warfarin, caffeine, and metoprolol
Timeframe: At Treatment Period 1 (CYP substrates alone, Day 1) and after 12 weeks of duvakitug (Treatment Period 2, Day 85)
AUClast for CYP isoform specific substrates midazolam, omeprazole, warfarin, caffeine, and metoprolol
Timeframe: At Treatment Period 1 (CYP substrates alone, Day 1) and after 12 weeks of duvakitug (Treatment Period 2, Day 85)
Secondary (7)
Duvakitug serum concentrations: Ctrough
tmax of CYP substrates alone and after duvakitug administration
t1/2 of CYP substrates alone and after duvakitug administration
tlast of CYP substrates alone and after duvakitug administration
Cmax of CYP substrates alone and after duvakitug administration
Show 2 moreShow less
Number of participants with anti-drug antibodies against duvakitug
Number of participants with TEAEs, TESAEs, TEAESIs, and TEAEs leading to permanent study intervention discontinuation
Arms and interventions
DuvakitugExperimental
Subcutaneous injection of duvakitug as per protocol and oral administration of caffeine, metoprolol, midazolam, omeprazole, warfarin and vitamin K as per protocol
Drugs: Duvakitug